Bone Biologics to Participate in H.C. Wainwright Investment Conference
News provided byBone Biologics Corporation · 1 min read
BURLINGTON, MA, Sept. 03, 2026 /CourierPR/ -- Bone Biologics Corporation, a developer of orthobiologic products for spine fusion markets, will be participating in the H.C. Wainwright 28th Annual Global Investment Conference, taking place from September 14 to 16, 2026, at the Lotte New York Palace Hotel.
Jeff Frelick, Chief Executive Officer of Bone Biologics, will engage in one-on-one meetings with investors during the conference dates. Additionally, a virtual presentation will be available on-demand starting September 11, 2026, at 7:00 AM Eastern Time for registered attendees via the conference platform.
Founded to pursue regenerative medicine for bone, Bone Biologics is working with select strategic partners to advance its research, particularly focusing on the preclinical research of the NELL-1 protein. The company is concentrating its development efforts on its bone graft substitute product for bone regeneration in spinal fusion procedures, with additional rights to trauma and osteoporosis applications.
Attendees can request a meeting and register for the conference by visiting the official website: <https://hcwevents.com/annualconference>.